Scarica l'app Stockscreener
8.66
0.35%
0.03
Dopo l'orario di chiusura:
8.63
-0.03
-0.35%
Precedente Chiudi:
$8.63
Aprire:
$8.75
Volume 24 ore:
60,233
Relative Volume:
0.86
Capitalizzazione di mercato:
$78.34M
Reddito:
$789.00K
Utile/perdita netta:
$5.70M
Rapporto P/E:
10.69
EPS:
0.81
Flusso di cassa netto:
$865.00K
1 W Prestazione:
-7.08%
1M Prestazione:
+2.24%
6M Prestazione:
-50.23%
1 anno Prestazione:
-37.23%
Intervallo 1D:
$8.60
$9.005
Intervallo di 1 settimana:
$8.60
$9.30
Portata 52W:
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
8.66 | 78.07M | 789.00K | 5.70M | 865.00K | 0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.10 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.91 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.30 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
289.65 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics schedules 2026 annual meeting for June 9 - Investing.com
Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date - TipRanks
Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
MCRB: Canaccord Genuity Maintains Buy Rating with $22 Target | MCRB Stock News - GuruFocus
MCRB Should I Buy - Intellectia AI
Exit Recap: Is Seres Therapeutics Inc impacted by rising rates2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Seres Therapeutics (NASDAQ:MCRB) Releases Earnings Results, Beats Expectations By $0.50 EPS - MarketBeat
Seres Therapeutics 2025 10-K: $0.8M Revenue, net income $5.70M - TradingView
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline - TipRanks
Seres (MCRB) Focuses on Advancing Biotherapeutics Portfolio - GuruFocus
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Seres Therapeutics: Fourth Quarter Earnings Overview - Bitget
Seres Therapeutics: Q4 Earnings Snapshot - KTVB
Layoff Tracker: Inovio Slims Down as Lead Asset Nears Market - BioSpace
Seres Therapeutics (MCRB) awards 56,250 stock options to officer - Stock Titan
Seres Therapeutics (MCRB) officer Brady Kelly reports stock holdings - Stock Titan
Seres Therapeutics Inc expected to post a loss of $2.11 a shareEarnings Preview - TradingView
Is Seres Therapeutics Incs ROE strong enough2025 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Rally Mode: Should I invest in Seres Therapeutics Inc before earningsGold Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Activity Recap: Should I invest in Seres Therapeutics Inc before earningsWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Aug Action: Does Seres Therapeutics Inc have declining or rising EPSMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Seres Therapeutics (MCRB) grants 75,000-share stock option to officer Henn - Stock Titan
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday - MarketBeat
Human Microbiome Therapeutics Market to Reach US$ 5.86 Billion - openPR.com
MCRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seres Therapeutics Announces Executive Leadership Changes and Promotions - The Globe and Mail
MCRB: Leadership transition and pipeline progress position the company for key clinical milestones in 2026 - TradingView
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates - The Manila Times
Seres Therapeutics appoints Kender as exec chair, interim CEO - National Today
[8-K] Seres Therapeutics, Inc. Reports Material Event | MCRB SEC FilingForm 8-K - Stock Titan
Seres Therapeutics, Inc. Announces Executive Changes, Effective March 2, 2026 - marketscreener.com
IPO Launch: Can STEL ride the EV waveQuarterly Trade Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageWhat's Next? - MarketBeat
MCRB Technical Analysis & ETF Price Forecast - Intellectia AI
Setup Watch: Can Seres Therapeutics Inc outperform under higher oil prices2025 Big Picture & Consistent Growth Stock Picks - baoquankhu1.vn
Seres down after pausing investments for lead program - MSN
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity - Stock Titan
Market Review: Will Seres Therapeutics Inc benefit from green energy policiesQuarterly Portfolio Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
$3.25+ Bn Human Microbiome Market Trends and Global Forecasts, 2035, Driven by Advancements in Microbiome Sequencing, Rising Investments in R&D, and Increasing Demand for Personalized Medicine - GlobeNewswire Inc.
Will Seres Therapeutics Inc. benefit from green energy policiesJuly 2025 Catalysts & Real-Time Buy Zone Alerts - mfd.ru
Is Seres Therapeutics Inc. stock a good choice for value investorsMarket Trend Review & Real-Time Volume Trigger Notifications - mfd.ru
Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MCRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Seres Therapeutics Status update Earnings Call Transcript - MarketBeat
Seres Pauses SER-155 Phase 2 Study, Cuts Costs - marketscreener.com
Seres Therapeutics Pauses SER-155 Investment, Cuts Workforce by 30% - Intellectia AI
Seres Therapeutics Stock Declines Amid Strategic Shift - Intellectia AI
Seres provides program and corporate updates and prioritizes emerging programs in inflammatory & immune diseases - marketscreener.com
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.99%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):